Treatment of patients with malignant lymphomas with monoclonal antibodies

Bone Marrow Transplantation

Volumn 25, Issue , 2000, Pages S50-S53

  Tesch, H ^a   Engert, A ^a   Manzke, O ^a   Diehl, V ^a   Bohlen, H ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Immunotherapy; Malignant lymphoma; Monoclonal antibodies

Indexed keywords

BISPECIFIC ANTIBODY; CD20 ANTIBODY; CD20 ANTIGEN; CYTOKINE; MONOCLONAL ANTIBODY; RADIOISOTOPE; TOXIN; UNCLASSIFIED DRUG;

B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; IMMUNOTHERAPY; LYMPHOMA; PRIORITY JOURNAL; RELAPSE; T CELL LYMPHOMA; T LYMPHOCYTE; VACCINATION;

ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOCONJUGATES; IMMUNOTHERAPY; IMMUNOTOXINS; LYMPHOMA; VACCINATION;

EID: 0033946561     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702355     Document Type: Article

References (39)

1. Drexler HG, Borkhardt A, Janssen JWG. Detection of chromosomal translocations in leukemia-lymphoma cells by polymerase chain reaction. Leuk Lymph 1995; 19: 359-380.
2. Tedder TF, Engel P. CD20: a regulator of cell-cycle progression and B lymphocytes. Immunol Today 1994; 15: 450-454.
3. Yao XR, Scott DW. Expression of protein tyrosine kinases in the Ig complex of anti-mu-sensitive and anti-mu-resistant Bcell lymphomas: role of the p55blk kinase in signaling growth arrest and apoptosis. Immunol Rev 1993; 132: 163-186.
4. Meeker TC, Lowder J, Maloney DG et al. A clinical trial of anti-idiotype therapy for B-cell malignancy. Blood 1995; 65: 1349-1363.
5. Brown SL, Miller RA, Horning SJ et al. Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood 1989; 73: 651-661.
6. Vuist WMJ, Levy R, Maloney DG. Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by their tumor expression of high levels of Bcl-2 protein. Blood 1994; 83: 899-906.
7. Rai KR, Hoffman M, Janson D et al. Immunosuppression and opportunistic infections (OI) in patients with chronic lymphocytic leukemia (CLL) following Campath 1-H therapy. Blood 1995; 10 (Suppl.): 1381.
8. Anagnostopoulos A, Fassas A, Papaminas N et al. Immunotherapy with Campath-1H for patients with lymphoproliferative disease. Blood 1995; 10 (Suppl.): 3297.
9. Winkler U, Jensen M, Manzke O et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999; 94: 2217-2224.
10. Kaminski MS, Zasadny KR, Francis IR et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996; 14: 1974-1981.
11. Press OW, Eary JF, Appelbaum FR et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. New Engl J Med 1993; 329: 1219-1224.
12. Press OW, Eary JF, Appelbaum FR et al. Phase II trial of 131I-Bi (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B-cell lymphomas. Lancet 1995; 346: 336-340.
13. White CA, Halpern SE, Parker BA et al. Radioimmunotherapy of relapsed B-cell lymphoma with yttrium-90 anti-idiotype monoclonal antibodies. Blood 1996; 87: 3640-3649.
14. Eiklid K, Olsnes S, Pihl A. Entry of lethal doses of abrin, ricin and modeccin into the cytosol of HeLa cells. Exp Cell Res 1980; 126: 321-326.
15. Endo Y, Tsurugi K. RNA N-glycosidase activity of ricin Achain. Mechanism of action of the toxic lectin ricin on eukaryotic ribosomes. J Biol Chem 1987; 262: 8128-8130.
16. Greenfield L, Bjorn MJ, Horn G et al. Nucleotide sequence of the structural gene for diphtheria toxin carried by corynebacteriophage beta. Proc Natl Acad Sci USA 1983; 80: 6853-6857.
17. FitzGerald D, Pastan I. Targeted toxin therapy for the treatment of cancer. J Natl Cancer Inst 1989; 81: 1455-1463.
18. Engert A, Diehl V, Schnell R et al. A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood 1997; 89: 403-410.
19. Milstein C, Cuello AC. Hybrid hybridomas and their use in immunohistochemistry. Nature 1983; 305: 537-541.
20. Fanger MW, Shen L, Graziano RF et al. Cytotoxicity mediated by human Fc receptors for IgG. Immunol Today 1989; 10: 92-97.
21. Schmidt M, Hynes NE, Groner B, Wels W. A bivalent singlechain antibody-toxin specific for ErbB-2 and the EGF receptor. Int J Cancer 1996; 65: 538-546.
22. Perez P, Hoffman RW, Shaw S. Specific targeting of cytotoxic T-cells by anti-T3 conjugates. Nature 1985; 316: 354-356.
23. Segal DM, Garrido MA, Perez P et al. Targeted cytotoxic cells as a novel form of cancer immunotherapy. Mol Immunol 1988; 25: 1099-1103.
24. Haagen IA, Geerars AJ, de Lau WBM et al. The efficacy of CD3 CD19 bispecific monoclonal antibody (BsAb) in a clonogenic assay: the effect of repeated addition of BsAb and interleukin-2. Blood 1995; 85: 3208-3212.
25. De Gast GC, Van Houten AA, Haagen IA et al. Clinical experience with CD3xCD19 bispecific antibodies in patients with B-cell malignancies. J Hematother 1995; 4: 433-437.
26. French RR, Hamblin TJ, Bell AJ et al. Treatment of B-cell lymphomas with combination of bispecific antibodies and saporin. Lancet 1995; 346: 223-224.
27. Ely P, Wallace PK, Givan AL et al. Bispecific-armed, interferon gamma-primed macrophage-mediated phagocytosis of malignant non-Hodgkin's lymphoma. Blood 1996: 87: 3813-3821.
28. Greene MI. Cellular and genetic basis of immune reactivity to tumor cells. Contemp Top Mol Immunol 1980; 11: 81-87.
29. Jerne N. Towards a network theory of the immune system. Ann Immunol 1974; 125: 373-389.
30. Kwak LW, Campbell MJ, Czerwinski DK et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunglobulin idiotype expressed by their tumors. New Engl J Med 1992; 327: 1209-1215.
31. Campbell MJ, Carroll W, Kon S et al. Idiotype vaccination against murine B-cell lymphoma. Humoral and cellular responses elicited by tumor derived immunoglobulin M and its molecular subunits. J Immunol 1987; 139: 2825-2833.
32. Campbell MJ, Esserman L, Byars NE et al. Development of a new therapeutic approach to B-cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor. Int Rev Immunol 1989; 4: 251-270.
33. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granocyte/macrophage colony stimulating factor plus interleukin-and downregulated by tumor necrosis factoralpha. J Exp Med 1994; 179: 1109-1118.
34. Hsu FJ, Benike C, Fagnoni F et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med 1996; 2: 52-58.
35. Griffiths AD, Williams SC, Hartley O et al. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J 1994; 13: 3245-3260.
36. Lonberg N, Taylor LD, Harding FA et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 1994; 368: 856-859.
37. Gribben JG, Freedman AS, Neuberg D et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. New Engl J Med 1991; 325: 1525-1533.
38. Vitetta ES, Stone M, Amlot P et al. Phase 1 immunotoxin trial in patients with B-cell lymphoma. Cancer Res 1991; 51: 4052-4058.
39. Grossbard ML, Lambert JM, Goldmacher VS et al. Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J Clin Oncol 1993; 11: 726.